Shin Nippon Biomedical Laboratories, Ltd.

TSE:2395 Voorraadrapport

Marktkapitalisatie: JP¥51.7b

Shin Nippon Biomedical Laboratories Beheer

Beheer criteriumcontroles 2/4

De CEO Shin Nippon Biomedical Laboratories is Ryoichi Nagata, benoemd in Jan1991, heeft een ambtstermijn van 33.83 jaar. bezit rechtstreeks 2.46% van de aandelen van het bedrijf, ter waarde ¥ 1.27B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.4 jaar en 9.4 jaar.

Belangrijke informatie

Ryoichi Nagata

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEO33.8yrs
Eigendom CEO2.5%
Management gemiddelde ambtstermijn2.4yrs
Gemiddelde ambtstermijn bestuur9.4yrs

Recente managementupdates

Recent updates

Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Sep 19
Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Earnings Miss: Shin Nippon Biomedical Laboratories, Ltd. Missed EPS By 88% And Analysts Are Revising Their Forecasts

Aug 09
Earnings Miss: Shin Nippon Biomedical Laboratories, Ltd. Missed EPS By 88% And Analysts Are Revising Their Forecasts

Little Excitement Around Shin Nippon Biomedical Laboratories, Ltd.'s (TSE:2395) Earnings As Shares Take 28% Pounding

Aug 06
Little Excitement Around Shin Nippon Biomedical Laboratories, Ltd.'s (TSE:2395) Earnings As Shares Take 28% Pounding

Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Jul 26
Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Jul 12
Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Shin Nippon Biomedical Laboratories' (TSE:2395) Sluggish Earnings Might Be Just The Beginning Of Its Problems

May 21
Shin Nippon Biomedical Laboratories' (TSE:2395) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Shin Nippon Biomedical Laboratories, Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 10
Shin Nippon Biomedical Laboratories, Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥30.00

Mar 12
Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥30.00

Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00

Feb 27
Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00

CEO

Ryoichi Nagata (66 yo)

33.8yrs

Tenure

JP¥144,061,000

Compensatie

Dr. Ryoichi Nagata, M.D., Ph D., F.F.P.M., serves as President & Director of Satsuma Pharmaceuticals, Inc. since June 8, 2023 Also serves as it's Chief Executive Officer and Group Financial Officer since 2...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Ryoichi Nagata
President33.8yrsJP¥144.06m2.46%
¥ 1.3b
Fumihiko Makino
Senior Executive Officer2.8yrsgeen gegevensgeen gegevens
Toshiyuki Iwata
Managing Executive Officerno datageen gegevensgeen gegevens
Shinji Nitanda
Senior MD of Corporate Development & Corporate Tax Administration and Director2.4yrsgeen gegevensgeen gegevens
Kyomi Nagatoshi
Senior Managing Executive Officerno datageen gegevensgeen gegevens
Ken Takanashi
Executive VP of Group Corporate Management & Global Business & Director20.4yrsgeen gegevens0.090%
¥ 46.4m
Satoshi Matsumoto
Managing Executive Officer & GM of Fisheries Divisionless than a yeargeen gegevensgeen gegevens
Hideshi Tsusaki
Senior MD1.8yrsgeen gegevensgeen gegevens
Terumasa Hirai
Managing Executive Officer & President and Representative Director of SNBL Ina Research Centerno datageen gegevensgeen gegevens
Shu-Ichi Kanazashi
Managing Executive Officerless than a yeargeen gegevensgeen gegevens
Eishi Tsunozaki
Senior MD & Directorno datageen gegevens0.043%
¥ 22.5m
Ichiro Nagata
Executive VPno datageen gegevens40.33%
¥ 20.8b

2.4yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 2395 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.4 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Ryoichi Nagata
President41.6yrsJP¥144.06m2.46%
¥ 1.3b
Shinji Nitanda
Senior MD of Corporate Development & Corporate Tax Administration and Director14.4yrsgeen gegevensgeen gegevens
Kyomi Nagatoshi
Senior Managing Executive Officerno datageen gegevensgeen gegevens
Ken Takanashi
Executive VP of Group Corporate Management & Global Business & Director21.9yrsgeen gegevens0.090%
¥ 46.4m
Hideshi Tsusaki
Senior MD10.4yrsgeen gegevensgeen gegevens
Eishi Tsunozaki
Senior MD & Director10.4yrsgeen gegevens0.043%
¥ 22.5m
Ichiro Nagata
Executive VP4.4yrsgeen gegevens40.33%
¥ 20.8b
Shinichi Fukumoto
Independent Outside Director9.4yrsgeen gegevens0.00096%
¥ 496.0k
Takashi Yamashita
Independent Outside Director9.4yrsgeen gegevens0.00096%
¥ 496.0k
Tsuyoshi Hanada
Independent Outside Director4.4yrsgeen gegevens0.0098%
¥ 5.1m
Keiko Totani
Independent Outside Director3.4yrsgeen gegevens0.0019%
¥ 992.0k
Chizuru Horishita
Independent Outside Directorless than a yeargeen gegevensgeen gegevens

9.4yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 2395 wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.4 jaar).